Rapid Discovery of Therapeutic Antibodies to Combat COVID-19 at Twist Bioscience

- Use synthetic biology to rapidly discover therapeutic antibodies
- Characterize binding kinetics, affinity, and epitope specificity on large antibody libraries
- Work with minimal amounts of sample
- Accelerate library-to-lead triage

At Twist Bioscience, our antibody engineering platform has revamped the discovery workflow to take advantage of the ongoing revolution in synthetic biology. In six weeks, we designed, produced, and screened a new antibody library and identified high affinity IgG and VHH candidates to the S1 spike protein of SARS-CoV-2, as well as to the human ACE2 cellular receptor to which SARS-CoV-2 mediates viral entry. Crucially, the high throughput and low reagent use of the Carterra LSA platform has allowed us to take full advantage of our antibody expression and purification workflow to characterize hundreds of the lead candidates by affinity, specificity, and epitope bin.

Presented by Tom Z. Yuan, PhD, Senior Scientist, Antibody Engineering, Twist Bioscience

[zapas]

What's your take on "Algernon Pharmaceuticals" (AGNPF), Covid-19 will not end with out therapeutics help